Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 60, Issue 2, Pages 261-271Publisher
SPRINGER
DOI: 10.1007/s00262-010-0935-9
Keywords
Renal cell carcinoma; Vaccine; TG4010; Immune response; MUC1; Cytokines
Categories
Funding
- Ligue contre le Cancer
- Pole de competitivite Medicen (Immucan)
- Canceropole d'Ile de France
- Centre d'Investigation Clinique en Biotherapie
Ask authors/readers for more resources
MUC1 over-expression in renal clear-cell carcinoma (RCC) is associated with poor prognosis. This phase II study determined the efficacy and tolerability of TG4010, a cancer vaccine based on a modified vaccinia virus expressing MUC1 and interleukin-2, in combination with cytokines, as first-line therapy in metastatic RCC. Thirty-seven patients with progressive, MUC1-positive RCC received TG4010 10(8) pfu/inj weekly for 6 weeks, then every 3 weeks until progression, when TG4010 was continued in combination with interferon-alpha 2a and interleukin-2. Assessments included clinical response (primary endpoint), safety, time to treatment failure (TTF), overall survival (OS), and immune response. No objective clinical responses occurred. Five of the 27 evaluable patients (18%) had stable disease for > 6 months with TG4010 alone and six of 20 patients (30%) had stable disease for > 6 months with TG4010 plus cytokines. Median TTF was 4.1, 3.6, and 9.3 months for monotherapy, combination therapy, and overall, respectively. Median OS was 19.3 months for all patients and 22.4 months combination therapy recipients. The most frequent TG4010-related adverse events were minor-to-moderate injection-site reactions, fatigue, and flu-like symptoms. Six of 28 patients showed a MUC1 CD4(+) T cell proliferative response during therapy. Anti-MUC1 CD8(+) T cells were detected before and after therapy in 3 and 4 patients, respectively. MUC1-specific CD8(+) T cell responses were associated with longer survival. Therapy with TG4010 plus cytokines appears to be feasible and well tolerated in patients with metastatic RCC. However, these data should be interpreted with caution, as additional prospective studies are necessary to clarify the clinical efficacy of this therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available